Dementia is a common disorder among older persons, and projections indicate that the number of patients with dementia in the United States will continue to grow. Alzheimer's disease and vascular dementia account for the majority of cases of dementia. After a thorough history and physical examination, including a discussion with other family members, a baseline measurement of cognitive function should be obtained. The Mini-Mental State Examination is the most commonly used instrument to document cognitive impairment. Initial laboratory evaluation includes tests for thyroid-stimulating hormone and vitamin [B.sub.12] levels. Structural neuroimaging with noncontrast computed tomography or magnetic resonance imaging also is recommended. Other testing should be guided by the history and physical examination. Neuropsychologic testing can help determine the extent of cognitive impairment, but it is not recommended on a routine basis. Neuropsychologic testing may be most helpful in situations where screening tests are normal or equivocal, but there remains a high level of concern that the person may be cognitively impaired.
Dementia persons and is a syndrome of gradual onset and continuing decline of higher cognitive functioning. It is a common disorder in older becomes more prevalent in each decade of life. Approximately 10 percent of adults 65 years and older, and 50 percent of adults older than 90 years, have dementia. It is common for older patients to present to family physicians with concerns of memory loss. With an accurate and timely diagnosis of dementia, appropriate therapies can be initiated to reduce further cognitive decline. Therefore, family physicians play a key role in evaluating patients with suspected dementia. Given conflicting recommendations about the initial evaluation of patients with dementia, the availability of genetic markers for Alzheimer's disease, and new neuroimaging methods such as positron emission tomography, confusion may arise concerning how best to evaluate these patients. (1-6) This article reviews the evidence regarding the initial evaluation of the patient who presents with memory loss.
Signs and Symptoms of Dementia
Patients often present with concerns of recent memory loss. However, it is not uncommon for a family member to bring these concerns to the physician because some patients deny their impairment or excuse the memory loss as a normal part of aging. The diagnosis of dementia can be suggested when there is an impairment in memory and an impairment of at least one other area of higher cognitive functioning (e.g., judgment, abstract thinking, complex task performance, agnosia, apraxia, visuospatial awareness, personality change in the context of deficits) that interferes with normal social and executive functioning in an otherwise alert person. (7)
Early symptoms that may suggest a dementing illness include difficulty in learning and retaining new information, handling complex tasks, reasoning (for otherwise simple problem-solving), and problems with spatial awareness (finding one's way around familiar places), language (specifically difficulty expressing oneself or getting "lost" in conversations), and behavior (usually passive, suspicious, or more irritable or aggressive than usual). (6)
Alzheimer's disease accounts for 50 to 60 percent of all dementing illnesses. Vascular dementias (e.g., major cerebrovascular insults, microvascular pathology) are com-mon in 15 to 20 percent of patients, and often occur with Alzheimer's disease. The combination of Alzheimer's disease and vascular dementia or other dementing disorders is termed "mixed dementias." Conditions that may cause dementia are listed by frequency in Table Less than 10 percent of dementias are caused by treatable conditions ("reversible dementia"). Because depression, vitamin [B.sub.12] deficiency, and hypothyroidism often are comorbid conditions, it is not uncommon to treat an apparently reversible dementia only to find that symptoms were really caused by Alzheimer's disease or vascular dementia.
Mental Status Examinations
Mental status examinations are used to mea-sure the degree of cognitive impairment. A number of instruments have been developed for this purpose. Five commonly used instruments and their characteristics are shown in Table 2. (9) These instruments measure performance in similar areas of cognitive function and take five to 10 minutes to administer and score. Each is reliable for ruling out dementia when results are negative.
MINI-MENTAL STATE EXAMINATION
The most frequently used mental state examination in North America is the Mini-Mental State Examination (MMSE). The MMSE measures many areas of cognitive functioning including memory, orientation to place and time, naming, reading, copying (visuospatial orientation), writing, and the ability to follow a three-stage command. It can be administered in five to 10 minutes and is scored from zero to 30 points. A score of fewer than 24 points signifies cognitive impairment, although the test can be adjusted for educational level. (10) The MMSE is more specific but less sensitive (i.e., gives more false negatives but fewer false positives) in highly educated individuals. It is avail-able online at http://www.minimental.com and http://www.aafp.org/afp/20010215/703.html.
BLESSED INFORMATION MEMORY CONCENTRATION
The Blessed Information Memory Concentration (BIMC) instrument primarily assesses orientation, memory, and concentration (counting forward and backward, and naming the months of the year in reverse order). (11) Errors are counted and can total from zero to 28. Making more than 10 errors indicates cognitive impairment.
BLESSED ORIENTATION MEMORY CONCENTRATION
The Blessed Orientation Memory Concentration instrument is a shortened version of the BIMC with six questions assessing orientation to time, recall of a short phrase, counting backward, and reciting the months in reverse order. (12) A weighted score of errors is calculated. As with the BIMC, making more than 10 errors is indicative of cognitive impairment.
SHORT TEST OF MENTAL STATUS
The Short Test of Mental Status (STMS) assesses orientation, attention, recall, calculation, abstraction, clock drawing, and copying. The STMS has a total score of 38. A score of 29 or lower indicates impaired cognitive function.
FUNCTIONAL ACTIVITIES QUESTIONNAIRE
Although it is not a mental status examination, the Functional Activities Questionnaire (FAQ) measures functional activities that may be impaired by dementia (e.g., ability to shop, cook, pay bills). (13) The FAQ is answered by a family member or friend who knows and has observed the patient. The "informant" is asked to rate the performance of the patient in 10 activities as someone who is dependent, requires assistance, or has difficulty but does independently. Scores range from zero to 30 with a cutoff of 9 (i.e., dependent in three or more activities) signifying impairment. This information may be useful in a clinical con-text, but the patient's cognitive function still needs to be evaluated.
Initial Laboratory Evaluation
The purpose of laboratory testing is to exclude potentially reversible causes of dementia. The American Academy of Neurology recommends two laboratory tests for the initial evaluation of the patient with suspected dementia--thyroid function and vitamin [B.sub.12] level. (3) The Sec-ond Canadian Consensus Conference on Dementia (CCCD) recommends obtaining results for complete blood cell count, thyroid-stimulating hormone level, serum electrolytes, serum calcium, and serum glucose to exclude potential infections or metabolic causes for cognitive impairment. (1) Other testing, such as serology for syphilis, Lyme disease titer, human immunodeficiency virus (HIV), urinalysis, culture and sensitivity, heavy metal assays, erythrocyte sedimentation rate, liver function, serum folic acid level, or other vita-min level assays should be performed only when clinical suspicion warrants.
A lumbar puncture is not recommended for routine evaluation, but should be con-sidered for patients with suspected neurosyphilis, cerebral vasculitis, HIV infection, slow-virus diseases, or cerebral Lyme disease. Routine testing for genetic markers such as apolipoprotein E is not recommended.
Neuroimaging may diagnose vascular disease, normal pressure hydrocephalus, tumors, abscess, or subdural hematoma. However, the yield from neuroimaging in identifying a potentially reversible cause of dementia is low. (3) Therefore, there is some controversy regarding the routine use of neuroimaging in the primary evaluation of dementia. The CCCD recommends the following criteria for neuroimaging: age younger than 60 years, atypical or rapid cognitive decline, recent head trauma, localized neurologic signs or symptoms, gait disturbance, urinary incontinence (early in the course of the dementia), use of anticoagulants, and history of cancer. (1) The American Academy of Neurology recommends that all patients have a magnetic resonance imaging study or noncontrast computed tomography as part of the initial evaluation. (3) The American College of Radiology recommends magnetic resonance imaging as the preferred study if one is chosen. (5)
Routine use of single photon emission computed tomography or positron emission tomography is not recommended by evidence-based guidelines or most experts. (1-5,8,10,12,14-16) Electroencephalography is indicated only if "slow-virus" or prion disease is suspected. Neuropsychologic Testing Neuropsychologic testing can comprehensively assess multiple domains of higher cognitive functioning including intelligence and behavioral functioning. A trained psychologist or psychometrician performs neuropsychologic testing. Higher cognitive functioning (logical reasoning, abstract and conceptual reasoning, visuospatial orientation, constructional ability, abstract thinking, memory, verbal reasoning, verbal fluency, etc.) is evaluated. Neuropsychologic testing has the potential to identify cognitive impairment objectively in patients with higher base-line cognitive abilities. It also may reveal subtle cognitive impairment in persons with suspected cognitive impairment or dementia and in persons at increased risk of cognitive impairment, (17) and may be useful in distinguishing patients with mild cognitive impairment from those with dementia.
Neuropsychologic testing may be considered as an adjunctive option for patients and families who are anxious to define and measure (in a standardized fashion) cognitive functioning and then monitor for changes over time. Other candidates for possible formal testing include persons who are not well educated, those who do not have English as their native language, and persons who are functioning "normally" or who are minimally impaired on screening. Although it can be useful in evaluating the impact of depression, anxiety, and other psychologic symptoms on cognitive functioning, (15) neuropsychologic testing is not recommended routinely for all patients with suspected dementia.
An algorithm to guide the initial evaluation of the patient with dementia is shown in Figure 1. In the majority of patients, a thorough history and physical examination will identify the most likely cause of cognitive decline. Although relatively uncommon, potentially treatable causes of dementia can be ruled out by further laboratory testing and neuroimaging. In many patients, reversible conditions such as hypothyroidism or depression are comorbid rather than being the actual cause of cognitive decline.
[FIGURE 1 OMITTED]
The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.
This article is one in a series coordinated by the Department of Family Practice at Michigan State University College of Human Medicine, East Lansing, Mich. Guest editor of the series is Mark Ebell, M.D., M.S.
(1.) Chertkow H, Bergman H, Schipper HM, Gauthier S, Bouchard R, Fontaine S, et al. Assessment of suspected dementia. Can J Neurol Sci 2001;28(suppl 1):S28-41.
(2.) Kawas CH. Clinical practice. Early Alzheimer's disease. N Engl J Med 2003;349:1056-63.
(3.) Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Neurology 2001;56:1143-53.
(4.) Santacruz KS, Swagerty D. Early diagnosis of dementia. Am Fam Physician 2001;63:703-13,717-8.
(5.) Braffman B, Drayer BP, Anderson RE, Davis PC, Deck MD, Hasso AN, et al. Dementia. Radiology 2000;215(suppl):525-33.
(6.) Leifer BP. Early diagnosis of Alzheimer's disease: clinical and economic benefits. J Am Geriatr Soc 2003;51 (5 suppl Dementia):S281-8.
(7.) Diagnostic and statistical manual of mental disorders, 4th ed. Washington, D.C.: American Psychiatric Association, 2000.
(8.) Friedland RP, Wilcock GK. Dementia. In: Evans JG, Williams TF, Beattie BL, Michel JP, Wilcock GK, eds. Oxford textbook of geriatric medicine. 2d ed. Oxford: Oxford University Press, 2000:922-32.
(9.) Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003;138:927-37.
(10.) Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269:2386-91.
(11.) Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
(12.) Katzman R, Brown T, Fuld P, Peck A, Schechter R, Shimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 1983;140:734-9.
(13.) Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-9.
(14.) Chui H, Zhang Q. Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology's practice parameters. Neurology 1997;49:925-35.
(15.) Agency for Health Care Policy and Research. Early identification of Alzheimer's disease and related dementias. Clin Pract Guidel Quick Ref Guide Clin 1996;(19):1-28.
(16.) Geldmacher DS, Whitehouse PJ. Evaluation of dementia. N Engl J Med 1996;335:330-6.
(17.) Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Neurology 2001;56:1133-42.
This clinical content con-forms to AAFP criteria for evidence-based continuing medical education (EB CME). EB CME is clinical content presented with practice recommendations supported by evidence that has been systematically reviewed by an AAFP-approved source.
ALAN M. ADELMAN, M.D., M.S., is a professor in the Department of Family and Community Medicine at Penn State University College of Medicine, Hershey, Pa., and is vice chair for academic affairs and research. He received his medical degree from Temple University School of Medicine, Philadelphia, and completed a family practice residency at Kaiser Foundation Hospital-Sunset in Los Angeles.
MEL P. DALY, M.D., is director of the subacute unit at the Greater Baltimore Medical Center and associate professor of medicine at Johns Hopkins University School of Medicine, Baltimore. He received his medical degree from Trinity College University of Dublin, Dublin, Ireland, and completed a family practice residency and a geriatric medicine fellowship at the University of Maryland, Baltimore.
Address correspondence to Alan M. Adelman, M.D., M.S., Department of Family and Community Medicine, Penn State University College of Medicine, 500 University Dr., H154, Hershey, PA 17033-0850 (e-mail: email@example.com). Reprints are not available from the authors.
COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group